Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates in bone diseases

R W Sparidans1, I M Twiss, S Talbot

  • 1Department of Clinical Pharmacy and Toxicology, Leiden University Medical Centre, The Netherlands.

Pharmacy World & Science : PWS
|November 20, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined spinal epidural anaesthesia for caesarean delivery of quadruplets: a case report.

International journal of obstetric anesthesia·2025
Same author

PI3K/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model.

Frontiers in cardiovascular medicine·2022
Same author

Bioanalysis of EGFRm inhibitor osimertinib, and its glutathione cycle- and desmethyl metabolites by liquid chromatography-tandem mass spectrometry.

Journal of pharmaceutical and biomedical analysis·2019
Same author

Profiling of how nociceptor neurons detect danger - new and old foes.

Journal of internal medicine·2019
Same author

Bioanalysis of ibrutinib, and its dihydrodiol- and glutathione cycle metabolites by liquid chromatography-tandem mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2018
Same author

Initial experience of dual maintenance immunosuppression with steroid withdrawal in vascular composite tissue allotransplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same journal

In Memoriam.

Pharmacy world & science : PWS·2018
Same journal

UKCPA News.

Pharmacy world & science : PWS·2018
Same journal

Severe akathisia as a side effect of metoclopramide.

Pharmacy world & science : PWS·2010
Same journal

Introduction of pharmaceutical expertise in a palliative care team in Sweden.

Pharmacy world & science : PWS·2010
Same journal

Cost reduction associated with restriction policy on dispensing intravenous esomeprazole in Lebanon.

Pharmacy world & science : PWS·2010
Same journal

Azathioprine-induced severe cholestatic hepatitis in patient carrying TPMT*3C polymorphism.

Pharmacy world & science : PWS·2010
See all related articles

Bisphosphonates are bone-targeting drugs that inhibit osteoclast activity, proving effective in treating Paget's disease, osteoporosis, and malignancy-related bone disorders. They offer therapeutic benefits with generally safe administration, though structural variations impact potency and potential side effects.

Area of Science:

  • Pharmacology
  • Bone Biology
  • Drug Development

Background:

  • Bisphosphonates are a class of drugs with a strong affinity for bone tissue.
  • They modulate calcium metabolism primarily by inhibiting osteoclast-mediated bone resorption.
  • This mechanism makes them valuable for treating various bone diseases.

Purpose of the Study:

  • To review the therapeutic applications of bisphosphonates in bone diseases.
  • To discuss their efficacy in conditions such as Paget's disease, osteoporosis, and malignancy-related bone disorders.
  • To highlight the safety profile and structural variations influencing bisphosphonate characteristics.

Main Methods:

  • Review of existing literature on bisphosphonate pharmacology and clinical use.
  • Analysis of data on bisphosphonate efficacy in reducing bone pain, fracture rates, and bone turnover.

Related Experiment Videos

  • Examination of safety data, including common side effects and drug-specific toxicities.

    • Main Results:

    • Bisphosphonates effectively reduce bone pain and turnover in Paget's disease (60-70%).
    • Oral bisphosphonates (etidronate, alendronate) decrease vertebral fracture rates in postmenopausal osteoporosis and increase spinal bone mass.
    • These drugs can lower serum calcium and manage skeletal complications in malignancy-associated bone diseases.

    Conclusions:

    • Bisphosphonates are effective in managing Paget's disease, osteoporosis, and malignancy-related bone disorders.
    • Therapeutic doses administered orally or intravenously are generally safe, with gastrointestinal disturbances being the most common side effect.
    • Structural differences among bisphosphonates significantly affect their potency and therapeutic/toxicological profiles, indicating future potential for drug development.